Antares Pharma, Inc. (NASDAQ:ATRS) Rating Increased to Buy at Vetr Inc.

Antares Pharma, Inc. (NASDAQ:ATRS) was upgraded by investment analysts at Vetr from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, July 18th. The firm currently has a $3.42 price objective on the specialty pharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 16.72% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Chardan Capital assumed coverage on Antares Pharma in a report on Friday, June 23rd. They set a “buy” rating and a $5.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a report on Friday, June 23rd. Finally, Raymond James Financial, Inc. assumed coverage on Antares Pharma in a report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 target price for the company. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $4.34.

Shares of Antares Pharma (NASDAQ ATRS) opened at 2.93 on Tuesday. The company’s 50-day moving average price is $3.14 and its 200-day moving average price is $2.77. Antares Pharma has a 52-week low of $1.03 and a 52-week high of $3.37. The stock’s market cap is $458.27 million.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The business had revenue of $13.42 million during the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. Analysts expect that Antares Pharma will post ($0.11) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://transcriptdaily.com/2017/08/13/vetr-inc-upgrades-antares-pharma-inc-nasdaqatrs-to-buy-updated-updated-updated.html.

In other Antares Pharma news, insider Fred M. Powell purchased 130,000 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were purchased at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the transaction, the insider now owns 331,434 shares of the company’s stock, valued at $924,700.86. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRS. Alliancebernstein L.P. acquired a new position in Antares Pharma during the second quarter valued at $119,000. Legal & General Group Plc acquired a new position in Antares Pharma during the second quarter valued at $120,000. MML Investors Services LLC raised its position in Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 30,000 shares during the last quarter. Credit Suisse AG acquired a new position in Antares Pharma during the first quarter valued at $146,000. Finally, National Planning Corp raised its position in Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the last quarter. 31.70% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply